Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/202941
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Caballero, Juan-Carlos | - |
dc.contributor.author | Sánchez Barba, Mercedes | - |
dc.contributor.author | Hernandez-Sánchez, Jesus M. | - |
dc.contributor.author | Such, Esperanza | - |
dc.contributor.author | Janusz, Kamila | - |
dc.contributor.author | Sanz, Guillermo | - |
dc.contributor.author | Cabrero, Mónica | - |
dc.contributor.author | Chillón, M. del Carmen | - |
dc.contributor.author | Cervera, José | - |
dc.contributor.author | Hurtado, Ana María | - |
dc.contributor.author | Jerez, Andrés | - |
dc.contributor.author | Calderón-Cabrera, Cristina | - |
dc.contributor.author | Valcárcel, David | - |
dc.contributor.author | Lumbreras, Eva | - |
dc.contributor.author | Abáigar, María | - |
dc.contributor.author | López Cadenas, Félix | - |
dc.contributor.author | Hernández, Jesús M. | - |
dc.contributor.author | Cañizo, María Consuelo del | - |
dc.contributor.author | Díez-Campelo, María | - |
dc.date.accessioned | 2020-03-06T08:11:04Z | - |
dc.date.available | 2020-03-06T08:11:04Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Annals of Hematology 98: 2151-2162 (2019) | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | http://hdl.handle.net/10261/202941 | - |
dc.description.abstract | Somatic mutations in patients with myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (HSTC) are associated with adverse outcome, but the role of chronic graft-versus-host disease (cGVHD) in this subset of patients remains unknown. We analyzed bone marrow samples from 115 patients with MDS collected prior to HSCT using next-generation sequencing. Seventy-one patients (61%) had at least one mutated gene. We found that patients with a higher number of mutated genes (more than 2) had a worse outcome (2 years overall survival [OS] 54.8% vs. 31.1%, p = 0.035). The only two significant variables in the multivariate analysis for OS were TET2 mutations (p = 0.046) and the development of cGVHD, considered as a time-dependent variable (p < 0.001), correlated with a worse and a better outcome, respectively. TP53 mutations also demonstrated impact on the cumulative incidence of relapse (CIR) (1 year CIR 47.1% vs. 9.8%, p = 0.006) and were related with complex karyotype (p = 0.003). cGVHD improved the outcome even among patients with more than 2 mutated genes (1-year OS 88.9% at 1 year vs. 31.3%, p = 0.02) and patients with TP53 mutations (1-year CIR 20% vs. 42.9%, p = 0.553). These results confirm that cGVHD could ameliorate the adverse impact of somatic mutations in patients with MDS with HSCT. | - |
dc.description.sponsorship | This work has been supported by Gerencia Regional de Salud de Castilla y León (GRS 1033/A/14), Instituto de Salud Carlos III - Fondo de investigación sanitaria (FIS PI17/01741), Instituto de Salud Carlos III - Contratos Río Hortega (CM17/0017), Instituto de Salud Carlos III & FEDER funds (PI16/01302), and CIBERONC Centro de Investigación Biomédica en Red Cáncer (CB16/12/00284). | - |
dc.language | eng | - |
dc.publisher | Springer Nature | - |
dc.rights | closedAccess | - |
dc.subject | Myelodysplastic syndromes | - |
dc.subject | Somatic mutations | - |
dc.subject | TP53 | - |
dc.subject | Allogeneic hematopoietic stem cell transplantation | - |
dc.subject | Chronic graft-versus-host disease | - |
dc.title | Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1007/s00277-019-03751-6 | - |
dc.relation.publisherversion | http://dx.doi.org/10.1007/s00277-019-03751-6 | - |
dc.identifier.e-issn | 1432-0584 | - |
dc.date.updated | 2020-03-06T08:11:04Z | - |
dc.contributor.funder | Junta de Castilla y León | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | Centro de Investigación Biomédica en Red Cáncer (España) | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100014180 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 29-mar-2024
WEB OF SCIENCETM
Citations
2
checked on 27-feb-2024
Page view(s)
177
checked on 18-abr-2024
Download(s)
25
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.